Supplies
Dopamine hydrochloride, disulfiram, rhodamine123, phloretin, and N-acetyl-L-cysteine have been obtained from Aladdin Industrial Company (Shanghai, China). Hydrogen peroxide (30%), ethanol (AR, ≥ 95%), and ammonia answer (AR, 25–28%) have been bought from Sinopharm Chemical Regent Co., Ltd (Shanghai, China). SH-PEG-Mannose (Mn, 5000 Da) was bought from Huateng Pharma (Hunan, China). 2’,7’-Dichlorofluorescin diacetate (DCFH-DA), calcein acetoxymethyl ester (Calcein-AM), propidium iodide (PI), and Enhanced ATP Assay Package have been bought from Beyotime Chemical Reagent (Jiangsu, China). Lysotracker was bought from Yeasen Biotech Co., Ltd (Shanghai, China). HMGB1 antibody and goat anti-Mouse lgG AF 488 have been offered by Abmart Co., Ltd (Shanghai, China). Antibodies for circulation cytometry have been bought from Biolegend, lnc (USA). In Vivo MAb anti-mouse PD-1 (CD279) was obtained from BioXcell (USA).
Preparation of DSF@CuPDA-PEGM
CuPDA nanoparticles have been ready by the oxidative polymerization and self-assembly of dopamine (DA) with Cu2+ chelation below the alkaline situation. Firstly, dopamine hydrochloride (380 mg, 2 mmol) and CuCl2·2H2O (28.4 mg, 0.17 mmol) have been dissolved in 10 mL of deionized water, respectively. Then, dopamine hydrochloride and CuCl2·H2O options have been added into a mix of ammonium hydroxide (3 mL), ethanol (40 mL), and deionized water (90 mL) at room temperature stirring for twenty-four h. CuPDA nanoparticles have been collected by centrifuging, washing, and freeze-drying.
SH-PEG-Mannose (5k) was modified to the floor of the CuPDA nanoparticles. Firstly, CuPDA NPs (20 mg) have been dispersed in 20 mL of Tris buffer (10 mM, pH 8.5) containing SH-PEG-Mannose (20 mg). The response carried on at room temperature for twenty-four h and CuPDA–PEGM was collected through centrifugation and washing.
To encapsulate the hydrophobic DSF, CuPDA-PEGM (20 mg) was dispersed in ethanol answer (10 mL) with DSF (10 mg) and stirred at room temperature for twenty-four h. The ensuing DSF@CuPDA-PEGM was collected by centrifugation and washing with ethanol and water.
Characterization of DSF@CuPDA-PEGM
A JEM-2010 F transmission electron microscope (TEM, JEOL, Japan) was employed for morphological characterization of nanoparticles. Aspect mapping was performed on FEI-Talos F200S. X-ray photoelectron spectroscopy (XPS) spectra have been obtained by ESCALAB 250Xi (Thermo Fischer). The hydrodynamic dimension and zeta potential of nanoparticles have been measured by the Zetasizer Nano sequence (Nano-ZS ZEN3600, Malvern). UV-Vis absorption spectra have been noticed on a VICTOR Nivo Multimode Microplate Reader (PerkinElmer). CuPDA-PEGM NPs have been incubated in PBS or DMEM with 10% FBS for 1 h and 24 h to research their stability, then the hydrodynamic sizes have been measured.
Hydrogen peroxide-responsive degradation and copper ion launch in vitro
CuPDA NPs (0.25 mg/mL) have been incubated with totally different quantities of H2O2 (0, 0.1, 1, 5, 10 mM) in aqueous options. After 72 h, UV-vis absorption spectra of options from 400 to 800 nm have been measured. Cu2+ concentrations in supernatants have been investigated by Inductively coupled plasma atomic emission spectrometer (ICP-AES). For various incubation occasions (6, 12, 24, 48, 72 h), the absorbance of CuPDA NPs at 500 nm was recorded.
To check the degradation behaviors, DSF@CuPDA-PEGM dispersions have been incubated within the buffers mimicking totally different environments (pH 5.0 with 100 µM H2O2, pH 6.5 with 100 µM H2O2, and pH 7.4 with 3.6 µM H2O2) over 72 h. After incubation (6, 12, 24, 48, 72 h), the absorbance of DSF@CuPDA-PEGM dispersion at 500 nm was recorded. To check DSF launch, DSF@CuPDA-PEGM (2 mg of DSF) was dispersed within the buffers (pH 7.4, 3.6 µM H2O2 or pH 6.5, 100 µM H2O2), after which dialyzed in 10 mL of corresponding buffers. At given time intervals, the discharge media have been collected and changed with contemporary buffers. The quantity of launched DSF was evaluated and calculated based on the reported methodology [26].
In vitro mobile uptake
Rhodamine123 was loaded on CuPDA-PEG or CuPDA-PEGM to discover in vitro mobile uptake. For Rh123@CuPDA-PEG and Rh123@CuPDA-PEGM synthesis, 3 mg Rhodamine123 was dissolved in 500 µL ethanol, which was later added into CuPDA-PEG or CuPDA-PEGM suspensions (10 mg/mL). After stirring in a single day, Rh123@CuPDA-PEG and Rh123@CuPDA-PEGM have been dialyzed in water for 2 days and freeze-dried to be used.
To analyze GLUT1-mediated mobile uptake, HCT116 cells have been seeded in confocal dishes (5 × 104 cells/effectively). After 24 h, cell media have been changed with contemporary media containing Rh123@CuPDA-PEG or Rh123@CuPDA-PEGM (1.25 µg/mL). For the phloretin inhibition group, the cells have been pretreated with phloretin for 12 h earlier than publicity to Rh123@CuPDA-PEGM. For the mannose competitors group, the cells have been publicity to Rh123@CuPDA-PEGM within the media containing mannose (4.5 g/L) for 4 h. After remedy for 4 h, the cells have been stained with Hoechst 33,342, after which noticed on a confocal. For circulation cytometry evaluation, HCT116 cells (2 × 105 cells per effectively) have been cultured in a 6-well plate for twenty-four h, and handled as talked about above earlier than circulation cytometry evaluation.
In vitro cytotoxicity and apoptosis assay
HCT116, HUVEC, L929, CT26, NCM460, and 3T3 cells have been seeded within the DMEM medium with 10% fetal bovine serum (FBS) at 37 °C in an incubator with 5% CO2. HCT116 L/OHP cells have been cultured in RPMI-1640 medium with 10% FBS at 37 °C below the environment of 5% CO2.
The cytotoxicity of various drug formulations (DSF, CuPDA-PEGM, DSF@CuPDA-PEG, DSF@CuPDA-PEGM) in direction of HCT116 cells, HCT116 L/OHP cells, HUVEC cells, L929 cells, Hela cells, MCF-7 cells and A549 cells have been measured by a CCK-8 equipment (Vazyme). Briefly, cells (6 × 103 cells per effectively) have been cultured in 96-well plates for twenty-four h. Then, the cell tradition media have been changed with media containing totally different formulations (0–5 µg/mL DSF, 0–50 µg/mL CuPDA-PEGM). After incubating for twenty-four h, the cell viability was evaluated by a CCK-8 assay based on the producer’s directions.
Cell apoptosis assay was performed by an Annexin V/PI equipment. First, HCT116 or HUVEC cells (2 × 105 cells per effectively) have been cultured in a 6-well plate for twenty-four h. DSF (2.5 µg/mL), CuPDA-PEGM (25 µg/mL), DSF@CuPDA-PEG (2.5 µg/mL DSF), DSF@CuPDA-PEGM (2.5 µg/mL DSF) have been utilized to deal with these cells. After 24 h, the cells have been washed, collected, and stained with Annexin V and PI for circulation cytometry evaluation.
For stay/useless staining, HCT116 or HUVEC cells (1 × 105 cells per effectively) have been cultured in a 12-well plate and incubated for twenty-four h. The cells have been handled as talked about above. After that, the media have been discarded and the cells have been stained with Calcein-AM and PI for 30 min earlier than remark by a fluorescence microscope.
The mechanisms of in vitro cell cytotoxicity
For intracellular ROS ranges detection, HCT116 cells (1 × 105 cells per effectively) have been seeded in a 12-well plate and incubated for twenty-four h, adopted by remedy with DSF@CuPDA-PEGM (1.25 µg/mL) for various occasions (1 h, 2 h, 4 h, 8 h, 24 h). DCFH-DA probe (10 µM) was used to point the mobile ROS of the handled cells.
To change the ROS content material in HCT116 cells, H2O2 and N-acetyl-L-cysteine (NAC) have been utilized. HCT116 cells (1 × 105 cells per effectively) have been seeded in a 12-well plate and incubated in a single day. Then the tradition media have been changed with contemporary medium containing 0.2 mM H2O2 or 0.5 mM NAC and incubated for 4 h. Afterward, the cells have been handled with serum-free media containing DCFH-DA (10 µM) and incubated for 20 min earlier than imaging utilizing a fluorescence microscope. For circulation cytometry evaluation, HCT116 cells (2 × 105 cells per effectively) have been cultured in a 6-well plate in a single day. Cells have been handled with the identical process as talked about above, after which the cells have been collected for circulation cytometry evaluation.
To analyze the influence of intracellular ROS on DSF@CuPDA-PEGM’s selective killing means, cells (6 × 103 cells per effectively) cultured in a 96-well plate have been pretreated with 0.2 mM H2O2 or 0.1 mM NAC, then cells have been incubated with DSF@CuPDA-PEGM (DSF, 0–5 µg/mL) for twenty-four h. Afterward, the cell viability was measured by a CCK-8 assay.
As a way to discover the cell demise mechanisms induced by DSF@CuPDA-PEGM, HCT116 cells have been pretreated with Z-VAD-FMK (30 µM) or rotenone (100 nM), after which uncovered to DSF@CuPDA-PEGM (DSF, 0–5 µg/mL). After incubation for twenty-four h, the cell viability was evaluated by a CCK-8 assay.
In vitro ICD impact
To evaluate the ICD impact of DSF@CuPDA-PEGM, ICD-related DAMPs (HMGB1 and ATP) have been evaluated in CT26 cells in vitro. CT26 cells have been handled with free DSF, CuPDA-PEGM, DSF@CuPDA-PEG, and DSF@CuPDA-PEGM (2.5 µg/mL of DSF), respectively. After 4 h, the cells have been washed, mounted, and stained with anti-HMGB1 major antibody, adopted by Alexa Fluor 488 secondary antibody based on the producer’s protocol.
After CT26 cells have been incubated with these drug formulations for five h, the media have been collected and centrifuged at 1000 rpm for five min. ATP contents within the supernatants have been examined utilizing an Enhanced ATP Assay Package based on the producer’s directions.
To judge DCs maturation, the tradition media of CT26 cells have been collected and centrifuged after remedy with free DSF, CuPDA-PEGM, DSF@CuPDA-PEG, and DSF@CuPDA-PEGM for twenty-four h. Then, DC2.4 cells have been handled with these situation media for twenty-four h. Lastly, the DCs have been collected and stained with anti-CD11c-BV421 and anti-CD86-PE antibodies. The proportion of mature DCs was decided by circulation cytometry.
Animals
Feminine BALB/c nude mice (6 weeks) have been obtained from Beijing Very important River Laboratory Animal Expertise Co., Ltd. (Beijing, China). Feminine BALB/c mice (6–8 weeks) have been offered by Liaoning Changsheng Biotechnology Co., Ltd. (Benxin, China). All animal experiments have been carried out based on the protocols accredited by the Animal Care and Use Committee of Huazhong College of Science and Expertise (Wuhan, China).
In vivo antitumor impact
To judge the in vivo therapeutic results of DSF@CuPDA-PEGM, subcutaneous HCT116 tumor-bearing fashions in BALB/c nude mice have been used. HCT116 cells (1.2 × 106 cells) have been injected into the precise infra-axillary dermis subcutaneously to develop fashions. Tumor-bearing mice have been randomly divided into 5 teams (n = 6): (1) PBS management, (2) free DSF, (3) CuPDA-PEGM, (4) DSF@CuPDA-PEG, (5) DSF@CuPDA-PEGM. The mice have been intravenously injected with 200 µL of the above formulations each three days for 4 occasions for the reason that tumor quantity reached roughly 100 mm3. The dosages of DSF and CuPDA-PEGM have been 3.75 mg/kg and 37.5 mg/kg, respectively. Physique weight and tumor quantity have been monitored each two days. Tumor quantity was calculated based on the next formulation: V = 1/2 × width2 × size. Mice have been sacrificed at day 18, main organs have been collected and stained with hematoxylin and eosin, whereas the tumors have been weighed and carried out with TdT-mediated dUTP nick-end labeling (TUNEL) staining.
In vitro biocompatibility
Hemolysis assay was carried out to judge the biocompatibility of CuPDA-PEGM. Crimson blood cells suspension (900 µL, 2%) was incubated with 100 µL CuPDA-PEGM (0–100 µg/mL) below vibration for 4 h at 37 °C. Then, the mixtures have been centrifuged at 3000 rpm for 10 min and the supernatants have been measured at 545 nm. PBS and Triton X-100 have been utilized because the adverse and constructive controls.
The cytotoxicity of CuPDA-PEGM NPs (0–100 µg/mL) in noncancerous cell traces (L929, NCM460, and 3T3) was evaluated by a CCK-8 equipment based on the strategies talked about above.
In vivo antitumor efficacy by DSF@CuPDA-PEGM/αPD-1 mixture
When CT26 tumor volumes reached round 80 mm3, mice have been handled with PBS, αPD-1, DSF@CuPDA-PEGM, DSF@CuPDA-PEGM/αPD-1, respectively (n = 6, 3.75 mg/kg of DSF, 100 µg of αPD-1 per mouse). The physique weight and tumor volumes of mice have been monitored on daily basis. On day 12, mice have been sacrificed and their tumors have been harvested for staining with CD8 antibody. Cells with pink fluorescence round blue nuclei have been thought to be CD8+ T cells.
To analyze the immune responses of mice, CT26 tumor-bearing BALB/c mice have been divided into 4 teams randomly (n = 4). DSF@CuPDA-PEGM (DSF: 3.75 mg/kg) have been intravenously injected two occasions on day 0 and day 3, and αPD-1 was intraperitoneally administered on day 1 and day 4 at a dose of 100 µg/mouse. Mice have been sacrificed on day 5. Their tumors and tumor-draining lymph nodes have been collected for circulation cytometry evaluation. The tumors have been pulverized and the collected cells have been washed with 1640 medium adopted by staining with particular antibodies together with CD4-BV605, and CD8a-APC. The lymph nodes have been obtained and picked up for CD11c-FITC and CD86-PE staining. The cells have been lastly analyzed by circulation cytometry.